# Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects

> **NCT02691325** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 22 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** GSK2269557 ELLIPTA DPI
- **DRUG:** Placebo ELLIPTA DPI
- **DRUG:** Activated charcoal

## Key facts

- **NCT ID:** NCT02691325
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-14
- **Primary completion:** 2016-06-05
- **Final completion:** 2016-06-05
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02691325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02691325, "Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02691325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*